Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study

Child's Nervous System

Volumn 31, Issue 8, 2015, Pages 1283-1289

  Hoffman, Lindsey M ^a   Fouladi, Maryam ^a   Olson, James ^b   Daryani, Vinay M ^c   Stewart, Clinton F ^c   Wetmore, Cynthia ^c   Kocak, Mehmet ^g   Onar Thomas, Arzu ^c   Wagner, Lars ^a   Gururangan, Sridharan ^e   Packer, Roger J ^d   Blaney, Susan M ^f   Gajjar, Amar ^c   Kun, Larry E ^c   Boyett, James M ^c   Gilbertson, Richard J ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f TEXAS CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Brain tumor; Notch; Pediatric; Recurrent

Indexed keywords

HEMOGLOBIN; MK 0752; NOTCH RECEPTOR; 3-(4-((4-CHLOROPHENYL)SULFONYL)-4-(2,5-DIFLUOROPHENYL)CYCLOHEXYL)PROPANOIC ACID; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BENZENE DERIVATIVE; ENZYME INHIBITOR; HES1 PROTEIN, HUMAN; HES5 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; PROPIONIC ACID DERIVATIVE; REPRESSOR PROTEIN; SECRETASE; SULFONE; TRANSCRIPTION FACTOR HES 1;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BRAIN STEM TUMOR; CANCER RECURRENCE; CARCINOMA; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRY SKIN; EPENDYMOMA; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; NAUSEA; NEUROECTODERM TUMOR; NEUTROPENIA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; GENE EXPRESSION REGULATION; METABOLISM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; TIME FACTOR; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; AMYLOID PRECURSOR PROTEIN SECRETASES; AREA UNDER CURVE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZENE DERIVATIVES; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MALE; PROPIONATES; RECEPTOR, NOTCH1; REPRESSOR PROTEINS; SULFONES; TIME FACTORS; TRANSCRIPTION FACTOR HES-1; YOUNG ADULT;

EID: 84937978938     PISSN: 02567040     EISSN: 14330350     Source Type: Journal    
DOI: 10.1007/s00381-015-2725-3     Document Type: Article

References (39)

1. Miele L (2006) Notch signaling. Clin Cancer Res 12:1074–1079. doi:10.1158/1078-0432.CCR-05-2570
2. Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97–106. doi:10.1038/nrclinonc.2010.196
3. Lu P, Bai X-C, Ma D et al (2014) Three-dimensional structure of human γ-secretase. Nature 512:166–170. doi:10.1038/nature13567
4. Tonon G, Modi S, Wu L et al (2003) t (11;19) (q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33:208–213. doi:10.1038/ng1083
5. Chen Y, McGee J, Chen X et al (2014) Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One 9:e98293. doi:10.1371/journal.pone.0098293
6. Fan X, Mikolaenko I, Elhassan I et al (2004) Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 64:7787–7793. doi:10.1158/0008-5472.CAN-04-1446
7. Hatakeyama J, Sakamoto S, Kageyama R (2006) Hes1 and Hes5 regulate the development of the cranial and spinal nerve systems. Dev Neurosci 28:92–101. doi:10.1159/000090756
8. Li Y, Hibbs MA, Gard AL et al (2012) Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and hippo pathway effectors by Notch1. Stem Cells 30:741–752. doi:10.1002/stem.1030
9. Cuevas IC, Slocum AL, Jun P et al (2005) Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 65:5070–5075. doi:10.1158/0008-5472.CAN-05-0240
10. Beschorner R, Waidelich J, Trautmann K et al (2013) Notch receptors in human choroid plexus tumors. Histol Histopathol 28:1055–1063
11. Fiaschetti G, Schroeder C, Castelletti D et al (2014) NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. Acta Neuropathol Commun 2:39. doi:10.1186/2051-5960-2-39
12. Kristoffersen K, Villingshøj M, Poulsen HS, Stockhausen M-T (2013) Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biol Ther 14:625–637. doi:10.4161/cbt.24595
13. Taylor MD, Poppleton H, Fuller C et al (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323–335. doi:10.1016/j.ccr.2005.09.001
14. Jones DTW, Jäger N, Kool M et al (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100–105. doi:10.1038/nature11284
15. Natarajan S, Li Y, Miller EE et al (2013) Notch1-induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma. Cancer Res 73:5381–5390. doi:10.1158/0008-5472.CAN-13-0033
16. Ignatova TN, Kukekov VG, Laywell ED et al (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193–206. doi:10.1002/glia.10094
17. Fan X, Khaki L, Zhu TS et al (2010) NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28:5–16. doi:10.1002/stem.254
18. LoRusso P, Demuth T (2009) E H Phase I study of the gamma secretase inhibitor MK-0752 in patients with metastatic breast and other advanced solid tumors. 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18–22 (abstr 3605)
19. Krop I, Demuth T, Guthrie T et al (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30:2307–2313. doi:10.1200/JCO.2011.39.1540
20. Schott AF, Landis MD, Dontu G et al (2013) Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 19:1512–1524. doi:10.1158/1078-0432.CCR-11-3326
21. Fouladi M, Stewart CF, Olson J et al (2011) Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 29:3529–3534. doi:10.1200/JCO.2011.35.7806
22. Skolnik JM, Barrett JS, Jayaraman B et al (2008) Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol 26:190–195. doi:10.1200/JCO.2007.12.7712
23. Bai F, Tagen M, Colotta C et al (2010) Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 878:2348–2352. doi:10.1016/j.jchromb.2010.07.019
24. Real PJ, Tosello V, Palomero T et al (2009) Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15:50–58. doi:10.1038/nm.1900
25. Pugh TJ, Weeraratne SD, Archer TC et al (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488:106–110. doi:10.1038/nature11329
26. Blackman SC, Podtelezhnikov A, Railkar RA Notch pathway inhibition with MK-0752 leads to dose- and time-dependent transcriptional alterations in proliferation, PI3K, and Wnt pathway genes in plucked human hair follicles. Proc Am Assoc for Cancer Res 51:(abst 26)
27. Balint K, Xiao M, Pinnix CC et al (2005) Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 115:3166–3176. doi:10.1172/JCI25001
28. Wang T, Holt CM, Xu C et al (2007) Notch3 activation modulates cell growth behaviour and cross-talk to Wnt/TCF signalling pathway. Cell Signal 19:2458–2467. doi:10.1016/j.cellsig.2007.07.019
29. Brechbiel J, Miller-Moslin K, Adjei AA (2014) Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev 40:750–759. doi:10.1016/j.ctrv.2014.02.003
30. Tremblay I, Paré E, Arsenault D et al (2013) The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells. PLoS One 8:e85502. doi:10.1371/journal.pone.0085502
31. Hales EC, Taub JW, Matherly LH (2014) New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal 26:149–161. doi:10.1016/j.cellsig.2013.09.021
32. Zhao N, Guo Y, Zhang M et al (2010) Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation. Oncol Rep 23:1443–1447
33. Jin R, Nakada M, Teng L et al (2013) Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. Neurosci Lett 534:316–321. doi:10.1016/j.neulet.2012.12.008
34. Fouladi M, Perentesis JP, Phillips CL et al (2014) A phase I trial of MK-2206 in children with refractory malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer 61:1246–1251. doi:10.1002/pbc.25023
35. Fouladi M, Laningham F, Wu J et al (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806–4812. doi:10.1200/JCO.2007.11.4017
36. Gu F, Ma Y, Zhang Z et al (2010) Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 23:671–676
37. McAuliffe SM, Morgan SL, Wyant GA et al (2012) Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 109:E2939–48. doi:10.1073/pnas.1206400109
38. Groeneweg JW, DiGloria CM, Yuan J et al (2014) Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth. Front Oncol 4:171. doi:10.3389/fonc.2014.00171
39. Hiddingh L, Tannous BA, Teng J et al (2014) EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget 5:363–374